BeiGene, Ltd. (BGNE)
NASDAQ: BGNE · IEX Real-Time Price · USD
143.93
-0.96 (-0.66%)
Jul 2, 2024, 4:00 PM EDT - Market closed
BeiGene Revenue
BeiGene had revenue of $2.76B in the twelve months ending March 31, 2024, with 77.42% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $751.65M with 67.85% year-over-year growth. In the year 2023, BeiGene had annual revenue of $2.46B with 73.65% growth.
Revenue (ttm)
$2.76B
Revenue Growth
+77.42%
P/S Ratio
5.73
Revenue / Employee
$260,625
Employees
10,600
Market Cap
15.83B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
Dec 31, 2019 | 428.21M | 229.99M | 116.03% |
Dec 31, 2018 | 198.22M | -40.17M | -16.85% |
Dec 31, 2017 | 238.39M | 237.32M | 22,179.16% |
Dec 31, 2016 | 1.07M | -7.75M | -87.86% |
Dec 31, 2015 | 8.82M | -4.22M | -32.37% |
Dec 31, 2014 | 13.04M | 1.89M | 16.93% |
Dec 31, 2013 | 11.15M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Molina Healthcare | 35.85B |
Baxter International | 14.89B |
Quest Diagnostics | 9.29B |
Illumina | 4.49B |
Waters | 2.91B |
Genmab | 2.57B |
United Therapeutics | 2.50B |
BioMarin Pharmaceutical | 2.47B |
BGNE News
- 18 days ago - BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024 - Business Wire
- 19 days ago - BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region - Business Wire
- 4 weeks ago - BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference - Business Wire
- 5 weeks ago - BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL - Business Wire
- 7 weeks ago - BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024 - Business Wire
- 7 weeks ago - BeiGene Reports First Quarter 2024 Financial Results and Business Updates - Business Wire
- 2 months ago - BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report - Business Wire
- 2 months ago - Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting - Business Wire